Nanobac Pharmaceuticals Incorporated Stock Buy Hold or Sell Recommendation
| NNBP Stock | USD 0.0001 0.00 0.00% |
Given the investment horizon of 90 days and your typical level of risk aversion, our recommendation regarding Nanobac Pharmaceuticals Incorporated is 'Strong Sell'. A buy or sell recommendation provided by Macroaxis is an automated analysis based on historical performance and your stated risk tolerance. It serves as guidance on whether to purchase or sell Nanobac Pharmaceuticals Incorporated within the specified time frame.
Check out Nanobac Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Nanobac and provide practical buy, sell, or hold advice based on investors' constraints. Nanobac Pharmaceuticals Incorporated. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
Nanobac |
Execute Nanobac Pharmaceuticals Buy or Sell Advice
The Nanobac recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Nanobac Pharmaceuticals Incorporated. Macroaxis does not own or have any residual interests in Nanobac Pharmaceuticals Incorporated or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Nanobac Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Not Rated
Nanobac Pharmaceuticals Trading Alerts and Improvement Suggestions
| Nanobac Pharmaceuticals generated a negative expected return over the last 90 days | |
| Nanobac Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Nanobac Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 17.62 K. Net Loss for the year was (6.58 M) with profit before overhead, payroll, taxes, and interest of 3.1 K. | |
| Nanobac Pharmaceuticals Incorporated currently holds about 3.93 K in cash with (910.89 K) of positive cash flow from operations. | |
| Nanobac Pharmaceuticals has a very weak financial position based on the latest SEC disclosures |
Nanobac Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Nanobac Pharmaceuticals or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Nanobac Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Nanobac stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.00 | |
β | Beta against Dow Jones | 0.00 | |
σ | Overall volatility | 0.00 | |
Ir | Information ratio | 0.00 |
Nanobac Pharmaceuticals Volatility Alert
At this time Nanobac Pharmaceuticals Incorporated exhibits very low volatility. Nanobac Pharmaceuticals Incorporated appears to be a penny stock. Although Nanobac Pharmaceuticals Incorporated may be, in fact, a solid short-term or long term investment, many penny stocks are speculative investment instruments that are often subject to artificial stock promotion and campaigns of hype which may lead to misinformation and misrepresentation. Please make sure you fully understand upside potential and downside risks of investing in Nanobac Pharmaceuticals Incorporated or similar risky assets. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswing without any event/news,and sudden news releases. We also encourage traders to check biographies and work history of company President, CEO or other officers before investing in high-volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Nanobac instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Nanobac Pharmaceuticals Fundamentals Vs Peers
Comparing Nanobac Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Nanobac Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Nanobac Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Nanobac Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Nanobac Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Nanobac Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Nanobac Pharmaceuticals to competition |
| Fundamentals | Nanobac Pharmaceuticals | Peer Average |
| Return On Asset | -0.37 | -0.14 |
| Operating Margin | (151.42) % | (5.51) % |
| Current Valuation | 124.75 K | 16.62 B |
| Price To Earning | (0.02) X | 28.72 X |
| Price To Sales | 7.08 X | 11.42 X |
| Revenue | 17.62 K | 9.43 B |
| Gross Profit | 3.1 K | 27.38 B |
| EBITDA | (3.97 M) | 3.9 B |
| Net Income | (6.58 M) | 570.98 M |
| Cash And Equivalents | 3.93 K | 2.7 B |
| Total Debt | 4.12 M | 5.32 B |
| Book Value Per Share | (0.01) X | 1.93 K |
| Cash Flow From Operations | (910.89 K) | 971.22 M |
| Number Of Employees | 1 | 18.84 K |
| Beta | -35.7 | -0.15 |
| Market Capitalization | 124.75 K | 19.03 B |
| Total Asset | 7.22 M | 29.47 B |
| Retained Earnings | (28.93 M) | 9.33 B |
| Working Capital | (6.71 M) | 1.48 B |
| Current Asset | 31 K | 9.34 B |
| Current Liabilities | 6.75 M | 7.9 B |
| Net Asset | 7.22 M |
Nanobac Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Nanobac . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 1.0E-4 | |||
| Day Typical Price | 1.0E-4 |
About Nanobac Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Nanobac Pharmaceuticals Incorporated? Buying financial instruments such as Nanobac Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Nanobac Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Advertising Thematic Idea Now
Advertising
Companies specializing in advertising, marketing and advertising services. The Advertising theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Advertising Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Nanobac Stock Analysis
When running Nanobac Pharmaceuticals' price analysis, check to measure Nanobac Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nanobac Pharmaceuticals is operating at the current time. Most of Nanobac Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Nanobac Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nanobac Pharmaceuticals' price. Additionally, you may evaluate how the addition of Nanobac Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.